Meet our researchers
The Australian Centre for Blood Diseases (ACBD) is a recognised leader in blood disease research, focusing on blood cancers, thrombosis and bleeding disorders. Our goals are to turn new discoveries into better patient outcome
Professor Harshal Nandurkar
Professor Harshal Nandurkar, haematologist, head of ACBD and vascular biology group leader, describes basic science and translational research being undertaken at The ACBD.
Dr Karen Alt
Dr Karen Alt, head of the nanotheranostics group, describes her group's research developing improved imaging techniques to better understand disease progression and associated therapies.
Dr Catherine Carmichael
Dr Catherine Carmichael, head of the Leukaemia modelling and therapeutic discovery group, describes her group’s research understanding the mechanisms of AML development, and identifying new ways to treat this blood cancer subtype.
Associate Professor Christoph Hagemeyer
Associate Professor Christoph Hagemeyer, head of the nanobiotechnology research group, and Dr Erik Westein , senior postdoctoral fellow, explain their research to stop pathological blood clotting.
Professor Andrew Perkins
Professor Andrew Perkins, haematologist and head of the Myelofibrosis and genomics research group, discusses his translational research in genomics and diagnostics for blood disorders.
Dr Donia Moujalled
Dr Donia Moujalled, Victorian Cancer Agency Mid-Career Fellow, explains her research in Acute Myeloid Leukemia evaluating BH3-mimetic combination therapies and their clinical application.
Dr Cedric Tremblay
Dr Cedric Tremblay, senior postdoctoral fellow, outlines his research in Acute Lymphoblastic Leukemia and how tumour cells evade chemotherapy treatment to cause relapsed disease.
Dr Matthew McCormack
Dr Matthew McCormack, head of the Acute leukaemia's stem cell group, describes his research examining the molecular basis of acute T cell Lymphoblastic leukemia and the role of transcription factors and gene expression changes in causing disease.
Professor Andrew Wei
Professor Andrew Wei, haematologist and head of the leukaemia translational research group, talks about the importance of genomics to identify mechanisms of disease progression and clinical trials using targeted therapies to improve patient outcomes.
Professor David Curtis
Professor David Curtis, haematologist and head of the stem cells biology group, outlines his research program to dissect the regulation of normal and leukaemic stem cells.
Associate Professor Ross Dickins
Associate Professor Ross Dickins, head of the Acute Leukaemia research group, describes his research focus in heamatopoiesis in acute leukaemia's and improving therapy outcome.
Professor Rob Medcalf
Professor Rob Medcalf, head of the molecular neurotrauma and haemostasis laboratory, explains his research interest in fibrinolysis-the process our bodies implement to remove blood clots.
Professor Huyen Tran
Professor Huyen Tran, haematologist and head of Haemostasis and thrombosis, outlines his research in thrombotic and bleeding disorders and examining novel therapeutic interventions for these diseases.
Dr Warwick Nesbitt
Dr Warwick Nesbitt, head of the haematology micro-platforms group, explains his research in clinical haematology diagnostics, automated microfluidic drug screening systems, and fundamental research into blood platelet mechanotransduction.